These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 35575164)

  • 21. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.
    Zhang S; Bi M
    Ann Palliat Med; 2020 Nov; 9(6):4081-4088. PubMed ID: 33302668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L; Zhou Z; Zeng X; Tan C; Liu Q
    Front Immunol; 2024; 15():1408928. PubMed ID: 39035009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Wang BC; Xiao BY; Li PC; Kuang BH; Chen WB; Li PD; Lin GH; Liu Q
    J Oncol; 2020; 2020():2368164. PubMed ID: 33061969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy.
    Zhang T; Tao L; Chen Y; Zhang S; Liu Y; Li Y; Wang R
    Clin Respir J; 2024 Aug; 18(8):e13819. PubMed ID: 39118429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small-cell lung cancer: A systematic review and meta-analysis.
    Xu Y; Chen M; Ding Y; Guo F; Chen M; Lu T
    J Clin Pharm Ther; 2022 Apr; 47(4):421-429. PubMed ID: 34734431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
    Hsu PC; Wu BC; Wang CC; Chiu LC; Chang CH; Liu PC; Wu CE; Kuo SC; Ju JS; Huang AC; Lin YC; Yang CT; Ko HW
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
    Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
    Yao Y; Li B; Song R; Yang L; Zou B; Wang L
    Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.
    Chen CR; Qi WX; Liu T; Tong X
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5857-5867. PubMed ID: 36066161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 34. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
    Wang BC; Fu C; Lin GH
    Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
    Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
    Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
    Arriola E; González-Cao M; Domine M; De Castro J; Cobo M; Bernabé R; Navarro A; Sullivan I; Trigo JM; Mosquera J; Crama L; Isla D
    Oncol Ther; 2022 Jun; 10(1):167-184. PubMed ID: 35032007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
    Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
    Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
    Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
    Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
    Zhong Y; Wu Q; Wu S; Xie X
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2465-2474. PubMed ID: 34533625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.